[go: up one dir, main page]

MX2017003406A - Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea. - Google Patents

Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.

Info

Publication number
MX2017003406A
MX2017003406A MX2017003406A MX2017003406A MX2017003406A MX 2017003406 A MX2017003406 A MX 2017003406A MX 2017003406 A MX2017003406 A MX 2017003406A MX 2017003406 A MX2017003406 A MX 2017003406A MX 2017003406 A MX2017003406 A MX 2017003406A
Authority
MX
Mexico
Prior art keywords
bone metastasis
treating bone
predicting
diseases
metastasis diseases
Prior art date
Application number
MX2017003406A
Other languages
English (en)
Inventor
Staub Eike
Straub Josef
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2017003406A publication Critical patent/MX2017003406A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)

Abstract

La presente invención proporciona un nuevo método para tratar enfermedades metastásicas óseas en un sujeto, en donde el método depende de manera preferente en si el sujeto muestra ciertos niveles de proteínas específicos en uno o más fluidos corporales antes o durante el tratamiento, en donde el tratamiento comprende la administración de al menos un inhibidor de integrina pan a? a un sujeto, un medicamento para el uso en los nuevos métodos, y un método para predecir el resultado de un tratamiento con al menos un inhibidor de integrina pan ay con base en los niveles de proteínas específicos en uno o más fluidos corporales del sujeto.
MX2017003406A 2014-09-17 2015-08-18 Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea. MX2017003406A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051525P 2014-09-17 2014-09-17
PCT/EP2015/001701 WO2016041616A1 (en) 2014-09-17 2015-08-18 A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases

Publications (1)

Publication Number Publication Date
MX2017003406A true MX2017003406A (es) 2017-06-19

Family

ID=53879459

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003406A MX2017003406A (es) 2014-09-17 2015-08-18 Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.

Country Status (14)

Country Link
US (3) US10435472B2 (es)
EP (1) EP3194972B1 (es)
JP (2) JP7397569B2 (es)
KR (1) KR20170055540A (es)
CN (1) CN106714835A (es)
AU (2) AU2015317411A1 (es)
BR (1) BR112017004729A2 (es)
CA (1) CA2961426C (es)
ES (1) ES2897782T3 (es)
IL (1) IL251077B (es)
MX (1) MX2017003406A (es)
RU (1) RU2017113001A (es)
SG (1) SG11201702132WA (es)
WO (1) WO2016041616A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106714835A (zh) 2014-09-17 2017-05-24 默克专利股份公司 治疗骨转移疾病的方法、其药物以及预测治疗骨转移疾病的临床结果的方法
EP3193927B1 (en) 2014-09-17 2020-11-25 Merck Patent GmbH A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3807172A4 (en) * 2018-06-15 2022-06-22 Clearwater Seafoods Limited Partnership INSULATED AND VENTILATED SHELLFISH STORAGE
JP2022524173A (ja) * 2018-09-05 2022-04-28 アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティー 血液癌を処置するための腫瘍溶解性ウイルスプラットフォーム
KR102433986B1 (ko) * 2020-02-27 2022-08-22 주식회사 베르티스 암의 진단용 조성물
GB202100194D0 (en) * 2021-01-07 2021-02-24 Cambridge Entpr Ltd Inhibition of T-Cell activity

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2204890T3 (es) 1991-03-06 2004-05-01 Merck Patent Gmbh Anticuerpos monoclonales humanizados.
EP0719859B1 (en) 1994-12-20 2003-07-02 MERCK PATENT GmbH Anti-alpha V-integrin monoclonal antibody
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US20040157799A1 (en) * 2001-05-02 2004-08-12 Seaman John J Pharmaceutical uses of bisphosphonates
JP2004002321A (ja) * 2002-03-11 2004-01-08 Takeda Chem Ind Ltd 性ホルモン依存性疾患治療剤
AU2003211877A1 (en) 2002-03-11 2003-09-22 Takeda Chemical Industries, Ltd. Remedies for sex hormone-dependent disease
WO2004090550A2 (en) * 2003-04-08 2004-10-21 Colotech A/S A method for detection of colorectal cancer in human samples
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
US20070269824A1 (en) 2006-03-02 2007-11-22 Jeffrey Albrecht Methods and systems for evaluating health risk factors by measurement of DNA damage and DNA repair
PT2101805E (pt) * 2007-01-18 2013-01-31 Merck Patent Gmbh Terapia específica e medicamento usando ligandos integrina para tratar o cancro
EP2526967A1 (en) 2007-07-17 2012-11-28 Merck Patent GmbH Engineered anti-alpha v-integrin hybrid antibodies
PT2368118E (pt) * 2008-12-23 2014-01-13 Merck Patent Gmbh Biomarcadores para inibidores com atividade anti-angiogénica
US20120039805A1 (en) 2009-02-20 2012-02-16 Pangea Biosciences, Inc. Therapeutics And Methods For Treating Neoplastic Diseases Comprising Determining The Level Of Caveolin-1 And/Or Caveolin-2 In A Stromal Cell Sample
EP2848700B1 (en) * 2009-07-24 2017-10-04 Geadic Biotec, AIE. Markers for endometrial cancer
JP5606537B2 (ja) * 2009-09-17 2014-10-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌患者における診断使用のための方法及び組成物
EP2606349A4 (en) * 2010-08-20 2014-04-30 Univ Jefferson AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY
ES2683347T3 (es) * 2011-02-11 2018-09-26 Merck Patent Gmbh Anticuerpo anti-integrina alfa-v para el tratamiento de cáncer de próstata
WO2012167028A2 (en) * 2011-06-02 2012-12-06 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
HK1200739A1 (en) * 2012-03-30 2015-08-14 霍夫曼-拉罗奇有限公司 Diagnostic methods and compositions for treatment of cancer
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
US20140255413A1 (en) * 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP3193927B1 (en) 2014-09-17 2020-11-25 Merck Patent GmbH A method of treating solid cancers and/or metastases thereof, medicaments therefore, and a method of predicting the clinical outcome of treating solid cancers and/or metastases thereof
CN106714835A (zh) 2014-09-17 2017-05-24 默克专利股份公司 治疗骨转移疾病的方法、其药物以及预测治疗骨转移疾病的临床结果的方法

Also Published As

Publication number Publication date
US11851492B2 (en) 2023-12-26
US10435472B2 (en) 2019-10-08
AU2021261844A1 (en) 2021-12-02
US20170298133A1 (en) 2017-10-19
EP3194972A1 (en) 2017-07-26
SG11201702132WA (en) 2017-04-27
BR112017004729A2 (pt) 2017-12-05
US20190338037A1 (en) 2019-11-07
CN106714835A (zh) 2017-05-24
CA2961426C (en) 2024-01-09
US11306146B2 (en) 2022-04-19
EP3194972B1 (en) 2021-04-14
JP2017530970A (ja) 2017-10-19
KR20170055540A (ko) 2017-05-19
AU2015317411A1 (en) 2017-04-27
CA2961426A1 (en) 2016-03-24
IL251077B (en) 2022-05-01
RU2017113001A3 (es) 2019-03-28
IL251077A0 (en) 2017-04-30
NZ730664A (en) 2023-12-22
JP7397569B2 (ja) 2023-12-13
ES2897782T3 (es) 2022-03-02
RU2017113001A (ru) 2018-10-17
WO2016041616A1 (en) 2016-03-24
JP2021143183A (ja) 2021-09-24
US20220275094A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
MX2017003406A (es) Metodo para tratar enfermedades de metastasis osea, medicamentos para las mismas, y metodo para predecir el resultado clinico para tratar enfermedades de metastasis osea.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
MX2023000050A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
SG11201606154UA (en) System and method for assuring patient medication and fluid delivery at the clinical point of use
SG10201800760UA (en) System and method for assuring patient medication and fluid delivery at the clinical point of use
MA40364A (fr) Polythérapie pour le traitement du cancer
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
EP4252742A3 (en) Fluticasone furoate in the treatment of copd
MX387839B (es) Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
EA202090260A1 (ru) Средства и способы для генотерапии aav у человека
HK1253320A1 (zh) 用於治療aml的藥物組合物和治療有此需要的對象中的aml的方法
MX2017003015A (es) Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.
MX2024008740A (es) Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv.
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2020006388A (es) Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.
BR112017007031A2 (pt) composição farmacêutica para administração subcutânea, método de tratamento de um paciente que sofre de um trauma ou doença de coagulação de sangue, kit de peças, e forma de dosagem de uma composição farmacêutica
WO2019053116A8 (en) Method for guidance of fluid therapy based on proadrenomedullin
Ito Investigation of a new treatment outcome index for tuberculosis
UA96567U (uk) Спосіб прогнозування зрощення перелому
Korostiy et al. Suicide behaviors in young people (сlinics, features of forming, methods of сorrection and prophylaxis)
UA94419U (uk) Спосіб прогнозування незрощення перелому
UA104420U (uk) Спосіб прогнозування зрощення перелому
UA106706U (uk) Спосіб прогнозування зрощення перелому
UA130638U (uk) Спосіб природного омолодження організму людини